KR20240005122A - 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 - Google Patents

아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 Download PDF

Info

Publication number
KR20240005122A
KR20240005122A KR1020237043884A KR20237043884A KR20240005122A KR 20240005122 A KR20240005122 A KR 20240005122A KR 1020237043884 A KR1020237043884 A KR 1020237043884A KR 20237043884 A KR20237043884 A KR 20237043884A KR 20240005122 A KR20240005122 A KR 20240005122A
Authority
KR
South Korea
Prior art keywords
formulation
acetaminophen
ppm
captisol
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237043884A
Other languages
English (en)
Korean (ko)
Inventor
제임스 디 피프킨
제럴드 엘 모셔
로저 라쥬스키
Original Assignee
사이덱스 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이덱스 파마슈티칼스, 인크. filed Critical 사이덱스 파마슈티칼스, 인크.
Priority to KR1020267020066A priority Critical patent/KR20260110251A/ko
Publication of KR20240005122A publication Critical patent/KR20240005122A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
KR1020237043884A 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 Ceased KR20240005122A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267020066A KR20260110251A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662395794P 2016-09-16 2016-09-16
US62/395,794 2016-09-16
KR1020197010786A KR20190065296A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형
PCT/US2017/051919 WO2018053358A1 (en) 2016-09-16 2017-09-15 Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197010786A Division KR20190065296A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267020066A Division KR20260110251A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Publications (1)

Publication Number Publication Date
KR20240005122A true KR20240005122A (ko) 2024-01-11

Family

ID=61619250

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237043884A Ceased KR20240005122A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형
KR1020197010786A Ceased KR20190065296A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형
KR1020267020066A Pending KR20260110251A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197010786A Ceased KR20190065296A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형
KR1020267020066A Pending KR20260110251A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Country Status (8)

Country Link
US (2) US12527755B2 (cg-RX-API-DMAC7.html)
EP (1) EP3512511A4 (cg-RX-API-DMAC7.html)
JP (3) JP7181185B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240005122A (cg-RX-API-DMAC7.html)
CN (2) CN116869983A (cg-RX-API-DMAC7.html)
AU (3) AU2017326519B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019002976A (cg-RX-API-DMAC7.html)
WO (1) WO2018053358A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023224112A1 (ja) * 2022-05-20 2023-11-23 株式会社ダイセル 液状医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
RU2173172C2 (ru) 1997-05-05 2001-09-10 Сайдекс Инк. Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
WO2009098716A2 (en) * 2008-01-17 2009-08-13 Aptuit Laurus Private Limited Stable pharmaceutical aqueous compositions
DK2277546T3 (en) * 2009-07-23 2015-08-17 Uni Pharma Kleon Tsetis Pharmaceutical Lab S A Stable, ready to use, injectable paracetamol formulation
WO2012037117A1 (en) * 2010-09-13 2012-03-22 Bev-Rx, Inc. Aqueous drug delivery system comprising off - flavor masking agent
ES2472697T3 (es) 2011-04-07 2014-07-02 Borealis Ag Composición de pol�mero reticulable de silano
MX353603B (es) 2012-02-28 2018-01-19 Cydex Pharmaceuticals Inc Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
CN102871994B (zh) * 2012-09-29 2015-07-29 中国科学院大连化学物理研究所 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法
BR102014005885B1 (pt) * 2014-03-13 2021-04-13 Biotec Biológica Indústria Farmacêutica Ltda E.P.P Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso
CN115154619B (zh) * 2016-02-04 2025-11-28 西泽普研究与发展有限责任公司 受控释放和层状的环糊精包合物媒介物

Also Published As

Publication number Publication date
RU2019107764A3 (cg-RX-API-DMAC7.html) 2021-01-15
CN116869983A (zh) 2023-10-13
JP7181185B2 (ja) 2022-11-30
AU2023203660A1 (en) 2023-07-06
KR20190065296A (ko) 2019-06-11
WO2018053358A1 (en) 2018-03-22
AU2025204233A1 (en) 2025-06-26
US12527755B2 (en) 2026-01-20
AU2017326519B2 (en) 2023-03-16
US20190255000A1 (en) 2019-08-22
AU2017326519A1 (en) 2019-04-11
EP3512511A1 (en) 2019-07-24
JP2022140780A (ja) 2022-09-27
CN110167543A (zh) 2019-08-23
MX2023003761A (es) 2023-04-26
US20260115157A1 (en) 2026-04-30
MX2019002976A (es) 2019-07-10
RU2019107764A (ru) 2020-10-16
JP2019532927A (ja) 2019-11-14
JP2024051102A (ja) 2024-04-10
CA3036989A1 (en) 2018-03-22
EP3512511A4 (en) 2020-05-20
KR20260110251A (ko) 2026-07-14

Similar Documents

Publication Publication Date Title
KR101767689B1 (ko) 항미생물 조성물
JP7597778B2 (ja) シクロデキストリン及びブスルファンを含有する組成物
US20260115157A1 (en) Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin
KR20180119610A (ko) 즉시 사용가능한 케토로락 제제
US20150238448A1 (en) Formulation of radioprotective alpha, beta unsaturated aryl sulfones
RU2772384C9 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
RU2772384C2 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
CA3036989C (en) Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin
RU2787621C2 (ru) Композиция, содержащая циклодекстрин и бусульфан
US20170368055A1 (en) Methods for treating infections
HK1213821B (en) Antimicrobial compositions

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104